Shares of Novavax, Inc. (NVAX Quick QuoteNVAX ) have skyrocketed 117.2% this year so far compared with the industry’s 0.8% rise.
Image Source: Zacks Investment Research
This rally in share price is primarily being driven by the company’s poten
There's no better time than now to invest in dividend stocks. And some of the best dividend stocks that beat the S&P 500's average yield of 2% can be found in the healthcare sector.
Global dividends fell by 12.2% in 2020 after the pandemic forced businesses and corporations to make a
Here's Advertisement
Popular coronavirus stock BioNTech (NASDAQ:BNTX) was a hit with investors on Tuesday. They bid the company’s share price up by 2.4% on an otherwise downbeat day for the stock market. News from across the Atlantic seemed to lift sentiment on the company’s prospects.
So what
Earlier that day, U.K. Prime Minister Boris Johnson mapped out his government’s plan to combat the coronavirus pandemic in the country through the fall and winter.
Ray Dalio, founder of Bridgewater Associates
Getty Images
The second quarter of 2021 saw America's billionaires adjust a number of their stock holdings, whether it was adding or reducing positions, initiating new stakes or hitting the exits. But one thing of note, in Q2 an
Shares of Novavax, Inc. (NVAX Quick QuoteNVAX ) have skyrocketed 117.2% this year so far compared with the industry’s 0.8% rise.
Image Source: Zacks Investment Research
This rally in share price is primarily being driven by the company’s poten
There's no better time than now to invest in dividend stocks. And some of the best dividend stocks that beat the S&P 500's average yield of 2% can be found in the healthcare sector.
Global dividends fell by 12.2% in 2020 after the pandemic forced businesses and corporations to make a
Ray Dalio, founder of Bridgewater Associates
Getty Images
The second quarter of 2021 saw America's billionaires adjust a number of their stock holdings, whether it was adding or reducing positions, initiating new stakes or hitting the exits. But one thing of note, in Q2 an
Shares of Apellis Pharmaceuticals, Inc. (APLS Quick QuoteAPLS ) were down 37.2% on Friday after the company announced top-line data from two phase III studies, namely, DERBY and OAKS, which is evaluating its targeted C3 therapy, pegcetacoplan for treating adult patients with geographic
Here's Advertisement